What should you know about liquid biopsy and ovarian cancer?

A liquid biopsy analyses material released by tumour cells into the bloodstream. In ovarian cancer, the result may provide molecular clues that help a team understand the tumour or consider a treatment pathway. It may be useful when obtaining a tissue sample is difficult, or when clinicians want to compare tumour-related changes over time. A result without a detected change does not rule out ovarian cancer and may not answer every treatment question.

Diagnosis and planning can also involve pelvic imaging, examination, tissue pathology, and genomic tumour profiling. In some families, BRCA genetic testing addresses inherited risk, which is a different question from testing DNA released by a tumour. Surgery and chemotherapy decisions depend on the complete clinical picture.

Ask whether your sample was tested for a specific alteration, a broader group of changes, or a marker used to monitor treatment. Find out whether the finding is actionable, uncertain, or not detected, and whether a tissue sample is needed to confirm it. Bring earlier pathology and scan reports to appointments. If treatment is being discussed, ask how the result relates to surgery, chemotherapy, or another option, and whether inherited genetic counselling is appropriate.

Contact your oncology team for new abdominal swelling, persistent vomiting, increasing pelvic pain, difficulty eating, or a marked change in bowel or bladder function. Seek urgent care for severe pain, repeated vomiting with inability to keep fluids down, fainting, heavy bleeding, or sudden breathing difficulty. These symptoms require clinical assessment regardless of the liquid-biopsy result.

What information can this liquid biopsy provide for my ovarian cancer? Does it replace tissue testing? Is this result about the tumour or inherited risk? Could it affect surgery or chemotherapy? When should the result be reassessed?